Funding transnational collaborative research through joint transnational calls is one of the major objectives of E-Rare. This is the most important and effective joint activity to enhance the cooperation between European scientists working on rare diseases and thus reducing the fragmentation of research in this field. E-Rare launches calls on a yearly basis. The topic and eligibility criteria are specified every year and therefore may vary from one call to the other.

Hydroxychloroquine (HCQ) in pediatric ILD

Project Coordinator

Dr von Hauner Children´s Hospital, University of Munich


Antonio Moreno Galdó Hospital Universitari Vall d’Hebron Barcelona, Spain
Katarzyna Krenke Medical University of Warsaw Warsaw, Poland
Renato Cutrera Bambino Gesù” Children Hospital Rome, Italy
Nural Kiper Hacettepe University Faculty of Medicine Ankara, Turkey
Zsolt Szépfalusi Medical University of Vienna Vienna, Austria
Teresa Bandeira Centro Hospitalar Lisboa Norte, Hospital de Santa Maria Lisboa, Portugal
Kai Kronfeld Medical School of the University Mainz Mainz, Germany

Among children with interstitial lung diseases (chILD) the surfactant dysfunction disorders play an important role, but no proven treatments are available. During the last 30 years and based on anecdotal reports, hydroxychloroquine, a drug usually used for malaria treatment, has been tried to treat chILD.
The goals of this project are to investigate if the start or the withdrawal of hydroxychloroquine treatment will alter the oxygenation compared to placebo in patients with surfactant dysfunction disorders. Among others, quality of life, and costs will be assessed. The study will be done by teams in Austria, Germany, Italy, Poland, Portugal, Spain and Turkey. We hope to establish a safe and effective way to treat these forms of chILD.

E-Rare 2012 - Created by Toussaint Biger